Literature DB >> 8978961

Interleukin 6: a possible marker of disease activity in adult onset Still's disease.

M A Scheinberg1, E Chapira, M L Fernandes, O Hubscher.   

Abstract

OBJECTIVE: Adult onset Still's disease (AOSD) is an inflammatory disorder with elevated serum acute phase proteins. Interleukin-6 is a major contributor to the acute phase response. We therefore examined the serum levels of CRP, SAA and interleukin-6 in active and inactive AOSD.
RESULTS: Active patients had significantly elevated CRP, SAA, and interleukin-6 values. After steroid treatment a marked reduction was observed in all three parameters. There was a close kinetics on the fluctuations of CRP and SAA, but not on IL-6.
CONCLUSION: Acute phase proteins and IL-6 are useful markers of disease activity in AOSD.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8978961

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  11 in total

Review 1.  Adult-Onset Still's Disease: Molecular Pathophysiology and Therapeutic Advances.

Authors:  Paolo Sfriso; Sara Bindoli; Paola Galozzi
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

2.  Correlation of serum CX3CL1 level with disease activity in adult-onset Still's disease and significant involvement in hemophagocytic syndrome.

Authors:  Tsuyoshi Kasama; Hidekazu Furuya; Ryo Yanai; Kumiko Ohtsuka; Ryo Takahashi; Nobuyuki Yajima; Yusuke Miwa; Kazuo Kobayashi
Journal:  Clin Rheumatol       Date:  2012-02-10       Impact factor: 2.980

3.  Glucocorticoid and cyclosporine refractory adult onset Still's disease successfully treated with tocilizumab.

Authors:  Kazuko Matsumoto; Takao Nagashima; Shino Takatori; Yuta Kawahara; Masaki Yagi; Masahiro Iwamoto; Hitoaki Okazaki; Seiji Minota
Journal:  Clin Rheumatol       Date:  2009-01-30       Impact factor: 2.980

4.  Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still's disease.

Authors:  D Y Chen; J L Lan; F J Lin; T Y Hsieh; M C Wen
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

Review 5.  Treatment of refractory adult-onset Still's disease with tocilizumab: report of two cases and review of the literature.

Authors:  Rene Thonhofer; Manuela Hiller; Horst Just; Markus Trummer; Cornelia Siegel; Christian Dejaco
Journal:  Rheumatol Int       Date:  2011-01-15       Impact factor: 3.580

Review 6.  An Update on the Pathogenic Role of Macrophages in Adult-Onset Still's Disease and Its Implication in Clinical Manifestations and Novel Therapeutics.

Authors:  Po-Ku Chen; Der-Yuan Chen
Journal:  J Immunol Res       Date:  2021-06-20       Impact factor: 4.818

7.  Adult Onset Still's Disease and Autoinflammation.

Authors:  Petros Efthimiou; L Nandini Moorthy; Clio P Mavragani; Dimitris Skokos; Bruno Fautrel
Journal:  Int J Inflam       Date:  2012-08-29

8.  Adult-Onset Still's Disease: From Pathophysiology to Targeted Therapies.

Authors:  Clio P Mavragani; Evangelos G Spyridakis; Michael Koutsilieris
Journal:  Int J Inflam       Date:  2012-06-26

Review 9.  Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence.

Authors:  Hubert de Boysson; Jérome Février; Amélie Nicolle; Christophe Auzary; Loïk Geffray
Journal:  Clin Rheumatol       Date:  2012-10-30       Impact factor: 3.650

10.  Severe Adult-onset Still Disease with Constrictive Pericarditis and Pleuritis That Was Successfully Treated with Tocilizumab in Addition to Corticosteroids and Cyclosporin A.

Authors:  Hoshimi Kawaguchi; Hiroto Tsuboi; Mizuki Yagishita; Toshihiko Terasaki; Mayu Terasaki; Masaru Shimizu; Fumika Honda; Ayako Ohyama; Hiroyuki Takahashi; Haruka Miki; Masahiro Yokosawa; Hiromitsu Asashima; Shinya Hagiwara; Yuya Kondo; Isao Matsumoto; Takayuki Sumida
Journal:  Intern Med       Date:  2017-12-21       Impact factor: 1.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.